Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for genetically driven neuromuscular diseases.

The company’s FORCE platform is designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS).

Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

In January, Dyne Therapeutics revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101, the company’s lead candidate, in patients with myotonic dystrophy type 1 (DM1).

Also Read: Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy

Dyne plans to begin a global Registrational Expansion Cohort with the potential to support a submission for U.S. Accelerated Approval based on biomarker and functional data in H1 2026.

Dyne leverages TfR1 Fab-conjugation for drug delivery to muscles. TfR1 is highly expressed in muscle cells. BMO analyst Kostas Biliouris acknowledges potential safety risks associated with TfR1-targeting (anemia, hemorrhage, kidney injury) but notes that the safety in Dyne’s clinical data appears acceptable.

Analyst Biliouris says Dyne’s major catalyst and investor debate revolves around the FDA’s decision on the DM1 regulatory pathway, as this dictates whether Dyne could enter the DM1 market concurrently or behind its competitor Avidity Biosciences, Inc (NASDAQ:RNA)

BMO assumes a traditional approval pathway and sees the DM1 market as large enough to accommodate multiple players, and Dyne could differentiate via potential CNS benefits.

BMO has initiated with an Outperform rating and a price target of $50.

The analyst models around $4.3 billion DYNE-101 peak-risk unadjusted WW sales in 2035.

Price Action: DYN stock is up 2.16% at $12.29 at the last check Wednesday.

Read Next:

Viking Holdings’ 2025 Nearly Sold Out, But Goldman Sachs Seeks More Pricing Clarity For 2026

Photo via Shutterstock.

Latest Ratings for DYN

Date Firm Action From To Oct 2020 JP Morgan Initiates Coverage On  Overweight Oct 2020 Stifel Initiates Coverage On  Buy Oct 2020 Jefferies Initiates Coverage On  Buy

View More Analyst Ratings for DYN

View the Latest Analyst Ratings

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Story Continues

Get the latest stock analysis from Benzinga?

This article Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

View Comments